ArticleTherapeutic advances in neurological disorders2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.
Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The European Union Summary of Product Characteristics (EU SmPC) for alemtuzumab in multiple sclerosis (MS) was revised in January 2020 under an Article 20 EU-pharmacovigilance procedure to include a revised indication, additional contraindications, and new monitoring requirements. Objectives: To evaluate adherence to the revised SmPC for alemtuzumab across four European countries. Design: Descriptive cohort study using secondary healthcare data recorded between January 2020 (date of alemtuzumab EU SmPC revision) and the latest database update in each data source (ranging from March 2022 to January 2024). Methods: Data are used from: the Czech Republic MS registry (ReMuS), a cohort study of patients treated with alemtuzumab in Germany (long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS (TREAT-MS)), chart review data from three United Kingdom (UK) centers, and administrative healthcare data from the Belgian Social Security database (L'Agence InterMutualiste-Het InterMutualistisch Agentschap (AIM-IMA)). Adherence to revised indications, contraindications, and safety monitoring was summarized descriptively. Results: Data from 2046 people with MS treated with at least one course of alemtuzumab were assessed. Of 155 patients evaluable for adherence to the indication, 66.7% met the revised indication in ReMuS ( Conclusion: Alemtuzumab was prescribed in accordance with the indication in 67%-88% of patients included in this study. It was prescribed in accordance with the listed contraindications in 78%-98% of courses included in the study. Adherence to the monitoring schedule is adequate to maintain the benefit-risk profile of alemtuzumab. Trial registration: This study was registered in the Heads of Medicines Agency European Medicines Agency (EMA) catalog (EUPAS42540). Results are available on the EMA website: https://catalogues.ema.europa.eu/node/3602/resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.